US approves first-in-class targeted AML therapy
US regulators have approved the first targeted therapy for patients with relapsed or refractory acute myeloid leukemia carrying a certain genetic mutation.
Read More
Tag: isocitrate dehydrogenase-1
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
